{"id":62011,"date":"2025-10-13T13:03:46","date_gmt":"2025-10-13T11:03:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-continues-to-transform-standards-of-care-for-patients-with-three-landmark-breast-cancer-trials-and-additional-data-across-industry-leading-adc-portfolio-at-esmo\/"},"modified":"2025-10-13T13:03:46","modified_gmt":"2025-10-13T11:03:46","slug":"daiichi-sankyo-continues-to-transform-standards-of-care-for-patients-with-three-landmark-breast-cancer-trials-and-additional-data-across-industry-leading-adc-portfolio-at-esmo","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/daiichi-sankyo-continues-to-transform-standards-of-care-for-patients-with-three-landmark-breast-cancer-trials-and-additional-data-across-industry-leading-adc-portfolio-at-esmo\/","title":{"rendered":"Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO"},"content":{"rendered":"
\n